Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sepracor Licenses Late-Stage Anti-Epileptic From Portuguese Pharma Bial

This article was originally published in The Pink Sheet Daily

Executive Summary

Late 2008/early 2009 NDA filing targeted for the new chemical entity as an adjunct therapy to improve control of epileptic seizures.

You may also be interested in...



Sunovion Sees Advantage For Aptiom As Unscheduled Epilepsy Drug

Dainippon subsidiary plans to launch its next-generation version of carbamazepine in the second half of 2014. Lack of classification as a controlled substance means more direct access to prescribers, company says.

Sepracor To Meet With FDA After Complete Response Letter For Epilepsy Drug Stedesa

Agency had extended the review of the seizure therapy by three months, but still needs additional information.

Sepracor To Meet With FDA After Complete Response Letter For Epilepsy Drug Stedesa

Agency had extended the review of the seizure therapy by three months, but still needs additional information.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS066760

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel